Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa

This study has been completed.
Sponsor:
Information provided by:
Kenta Biotech Ltd
ClinicalTrials.gov Identifier:
NCT00851435
First received: February 25, 2009
Last updated: July 29, 2009
Last verified: July 2009

February 25, 2009
July 29, 2009
February 2008
July 2009   (final data collection date for primary outcome measure)
Assessment of physical examination, laboratory parameters, vital signs, ECG and any adverse at repeated times since the screening phase till the end of the study. [ Time Frame: 30 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00851435 on ClinicalTrials.gov Archive Site
  • To confirm the therapeutic plasma concentration of KBPA-101 [ Time Frame: 30 days ] [ Designated as safety issue: No ]
  • To ascertain the therapeutic efficacy of KBPA-101 given in addition to standard care for hospital acquired pneumonia [ Time Frame: 30 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa
A Non-comparative Open Pilot Trial to Assess the Safety and Pharmacokinetics of up to Three Single Doses of AERUMAB 11 (KBPA-101) in Patients With Hospital Acquired Pneumonia Caused by Serotype O11 P. Aeruginosa

The objectives of this open study are to assess the safety, tolerability, pharmacokinetics and clinical outcome of patients who have HAP caused by Pseudomonas aeruginosa serotype O11 after three separate administrations of KBPA-101 every third day in addition of standard of care antibiotic treatment.

Hospital acquired pneumonia (HAP) is a pneumonia occurring 48 hours or more after hospital admission. HAP occurs in patients on conventional hospital wards and in intensive care units (ICU), some of them associated to mechanical ventilation, known as Ventilator Associated Pneumonia (VAP). VAP is the most common infection on intensive care units representing 82% of HAP cases. Pseudomonas aeruginosa is one of the most frequent pathogens involved in ICU-HAP and despite of adequate treatment its crude mortality remains as high as 70% of the cases.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Pneumonia
  • Ventilator Associated Pneumonia
Biological: KBPA-101
1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
Experimental: KBPA-101, a monoclonal antibody
1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
Intervention: Biological: KBPA-101
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
July 2009
July 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female ≥ 18 years of age
  • Patients under intensive care management with hospital acquired pneumonia
  • Microbiological diagnosis of P. aeruginosa serotype O11 HAP by lower respiratory tract specimen (BAL or miniBAL) and presence of a new or progressing pulmonary infiltrate, plus one of the three following criteria: a) fever greater than 38ºC, b) WBC greater than 10,000/mm3, or c) purulent sputum
  • In non-intubated patients confirmed microbiological diagnosis of P. aeruginosa serotype O11 HAP by endotracheal aspirate (ETA) and modified clinical pulmonary infection score (CPIS) higher than 6 points
  • Patient is expected to survive longer than 72 hours
  • Written informed consent provided by the patient or by the relatives or the designated trusted person

Exclusion Criteria:

  • Use of any investigational drug within 30 days preceding the first dose of KBPA-101, or planned use during the study and safety follow-up periods
  • Existence of any surgical or medical condition that might render the patient unduly susceptible to possible toxicity from the monoclonal antibody, including septic shock with unstable hemodynamics,
  • Patients with a known complement deficiency associated with systemic lupus erythematosus, paroxysmal nocturnal hemoglobinuria, hereditary angioedema, membranoproliferative glomerulonephritis, collagen vascular disease, autoimmune hepatitis, primary biliary cirrhosis, scleroderma, or recurrent Neisserial infections
  • Confirmed Human Immunodeficiency Virus (HIV) infection
  • Transplant patients and/or simultaneous treatment with systemic immuno-suppressive drugs.
  • Patients with a known liver function deficiency, e.g. associated with liver cirrhosis (Child Pugh B or C) or acute hepatitis
  • Administration of poly- or mono-immunoglobulins within the three months preceding the first dose of study drug or planned administration during the study period
  • Neutropenia
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Switzerland
 
NCT00851435
KB-101-002
No
Violetta Georgescu, Kenta Biotech Ltd
Kenta Biotech Ltd
Not Provided
Study Director: Violetta Georgescu Kenta Biotech Ltd
Kenta Biotech Ltd
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP